source
- Epilepsy drug from Ovid and Takeda receives fresh start under Perceptive-backed ventureAfter about 26 months since two Phase 3 trials failed, the epilepsy treatment candidate originally developed by Ovid Therapeutics and Takeda has been removed from their pipelines. Investment firm…
- Italy’s life‑science sector gains clinical strength and venture capital but still trails Europe’s leadersIn a recent episode of BioSpace’s Denatured podcast, host Jennifer C. Smith‑Parker talks with Diana Saraceni of Panakès Partners and Fabrizio Calisti of Angelini Ventures about Italy’s life‑science…